Fig. 10

circEHD2-ASO inhibits the growth of RCC in vivo. A, Schematic illustration of tumor inoculation and circEHD2-ASO treatment in subcutaneous xenograft model and orthotopic xenograft model. B–E, Representative images of xenograft tumors (B), dissected tumors (C), the volume of tumors (D), and tumor weights (E) in subcutaneous xenograft model treated with ASO-control (n = 6/group) and circEHD2-ASO (n = 6/group), respectively. F-H, Representative images of in vivo bioluminescence imaging (F), the mean photon counts (G), and gross appearance of orthotopic tumor (H) in orthotopic xenograft model treated with ASO-control (n = 4/group) and circEHD2-ASO (n = 4/group), respectively. I, A schematic model showing the mechanism of EVs-circEHD2 mediated the progression of RCC. FUS mediated the biogenesis of circEHD2, then circEHD2 enhanced the growth of RCC through the circEHD2/YWHAH/YAP/SOX9 pathway. While hnRNPA2B1 mediated the packaging of circEHD2 into EVs, and EVs-circEHD2 promote metastasis of RCC by converting fibroblasts to CAFs. *, P < 0.05; **, P < 0.01; ***, P < 0.001